Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2020 - 2027
Purpose Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology...
FDG-PET | SURVIVAL | ABVD | ONCOLOGY | CLINICAL-TRIALS | BEACOPP | DISEASE | INTENSITY | RADIOTHERAPY | INTERNATIONAL PROGNOSTIC SCORE | CHEMOTHERAPY | Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Vinblastine - administration & dosage | Young Adult | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Radiopharmaceuticals | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - administration & dosage | Bleomycin - administration & dosage | Positron-Emission Tomography - methods | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fluorodeoxyglucose F18 | Neoplasm Staging | Granulocyte Colony-Stimulating Factor - administration & dosage | Index Medicus | Dxst3 | Timg2 | Bios3 | Hema13 | ORIGINAL REPORTS | Hema11
FDG-PET | SURVIVAL | ABVD | ONCOLOGY | CLINICAL-TRIALS | BEACOPP | DISEASE | INTENSITY | RADIOTHERAPY | INTERNATIONAL PROGNOSTIC SCORE | CHEMOTHERAPY | Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Middle Aged | Vinblastine - administration & dosage | Young Adult | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Radiopharmaceuticals | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - administration & dosage | Bleomycin - administration & dosage | Positron-Emission Tomography - methods | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fluorodeoxyglucose F18 | Neoplasm Staging | Granulocyte Colony-Stimulating Factor - administration & dosage | Index Medicus | Dxst3 | Timg2 | Bios3 | Hema13 | ORIGINAL REPORTS | Hema11
Journal Article
1996, ISBN 9780721648132, xv, 158
Book
European Journal of Neuroscience, ISSN 0953-816X, 04/2017, Volume 45, Issue 7, pp. 922 - 931
Although certain drugs of abuse are known to disrupt brain glucose metabolism (BGluM), the effects of opiates on BGluM are not well characterized. Moreover,...
brain imaging | brain energy metabolism | opiate addition | drug self‐administration | drug self-administration | 2-DEOXYGLUCOSE | SMALL ANIMAL PET | NALOXONE | NEUROSCIENCES | ADDICTION | DEPENDENCE | POSITRON-EMISSION-TOMOGRAPHY | NUCLEUS | RECEPTORS | WITHDRAWAL | BRAIN | Anesthetics, Inhalation - pharmacology | Fluorodeoxyglucose F18 - pharmacokinetics | Radiopharmaceuticals - pharmacokinetics | Anesthetics, Inhalation - administration & dosage | Isoflurane - pharmacology | Morphine - pharmacology | Substance Withdrawal Syndrome - etiology | Anesthesia, Intravenous - adverse effects | Analgesics, Opioid - pharmacology | Rats | Isoflurane - adverse effects | Male | Anesthetics, Inhalation - adverse effects | Corpus Striatum - metabolism | Rats, Sprague-Dawley | Positron Emission Tomography Computed Tomography | Analgesics, Opioid - adverse effects | Animals | Analgesics, Opioid - administration & dosage | Corpus Striatum - drug effects | Corpus Striatum - diagnostic imaging | Morphine - administration & dosage | Morphine - adverse effects | Glucose metabolism | Brain research | PET imaging | Physiological aspects | Anesthesia | Morphine | Glucose | Dextrose | Cerebellum | Brain | Cortex (olfactory) | Drug abuse | Basal ganglia | Intravenous administration | Mesencephalon | Emission analysis | Stimulation | Opiates | Hypothalamus | Infusion | Computed tomography | Rodents | Neostriatum | Thalamus | Defecation | Jugular vein | Self-administration | Narcotics | Therapeutic applications | Positron emission | Injection | Metabolism | Isoflurane | Ganglia | Emissions control | Positron emission tomography | Hippocampus
brain imaging | brain energy metabolism | opiate addition | drug self‐administration | drug self-administration | 2-DEOXYGLUCOSE | SMALL ANIMAL PET | NALOXONE | NEUROSCIENCES | ADDICTION | DEPENDENCE | POSITRON-EMISSION-TOMOGRAPHY | NUCLEUS | RECEPTORS | WITHDRAWAL | BRAIN | Anesthetics, Inhalation - pharmacology | Fluorodeoxyglucose F18 - pharmacokinetics | Radiopharmaceuticals - pharmacokinetics | Anesthetics, Inhalation - administration & dosage | Isoflurane - pharmacology | Morphine - pharmacology | Substance Withdrawal Syndrome - etiology | Anesthesia, Intravenous - adverse effects | Analgesics, Opioid - pharmacology | Rats | Isoflurane - adverse effects | Male | Anesthetics, Inhalation - adverse effects | Corpus Striatum - metabolism | Rats, Sprague-Dawley | Positron Emission Tomography Computed Tomography | Analgesics, Opioid - adverse effects | Animals | Analgesics, Opioid - administration & dosage | Corpus Striatum - drug effects | Corpus Striatum - diagnostic imaging | Morphine - administration & dosage | Morphine - adverse effects | Glucose metabolism | Brain research | PET imaging | Physiological aspects | Anesthesia | Morphine | Glucose | Dextrose | Cerebellum | Brain | Cortex (olfactory) | Drug abuse | Basal ganglia | Intravenous administration | Mesencephalon | Emission analysis | Stimulation | Opiates | Hypothalamus | Infusion | Computed tomography | Rodents | Neostriatum | Thalamus | Defecation | Jugular vein | Self-administration | Narcotics | Therapeutic applications | Positron emission | Injection | Metabolism | Isoflurane | Ganglia | Emissions control | Positron emission tomography | Hippocampus
Journal Article
Biological Psychiatry, ISSN 0006-3223, 2007, Volume 62, Issue 8, pp. 878 - 883
Background Sigma-1 receptors might be implicated in the pathophysiology of psychiatric diseases, as well as in the mechanisms of action of some selective...
Psychiatry | SSRI | sigma-1 receptor | paroxetine | occupancy | Fluvoxamine | PET | DELUSIONAL DEPRESSION | NEGATIVE SYMPTOMS | PSYCHIATRY | AFFECTIVE-DISORDERS | SCHIZOPHRENIA | fluvoxamine | NEUROSCIENCES | CNS SIGMA RECEPTORS | SEROTONIN REUPTAKE INHIBITORS | ANTIDEPRESSANTS | LIGANDS | PSYCHOTIC DEPRESSION | BINDING-PROPERTIES | Serotonin Uptake Inhibitors - metabolism | Brain - diagnostic imaging | Fluvoxamine - metabolism | Humans | Male | Piperazines - metabolism | Positron-Emission Tomography | Receptors, sigma - genetics | Paroxetine - metabolism | Brain - metabolism | Dose-Response Relationship, Drug | Paroxetine - administration & dosage | Radiopharmaceuticals - metabolism | Fluvoxamine - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Adult | Polymorphism, Single Nucleotide | Receptors, sigma - metabolism | PET imaging | Serotonin uptake inhibitors | Radioactive tracers
Psychiatry | SSRI | sigma-1 receptor | paroxetine | occupancy | Fluvoxamine | PET | DELUSIONAL DEPRESSION | NEGATIVE SYMPTOMS | PSYCHIATRY | AFFECTIVE-DISORDERS | SCHIZOPHRENIA | fluvoxamine | NEUROSCIENCES | CNS SIGMA RECEPTORS | SEROTONIN REUPTAKE INHIBITORS | ANTIDEPRESSANTS | LIGANDS | PSYCHOTIC DEPRESSION | BINDING-PROPERTIES | Serotonin Uptake Inhibitors - metabolism | Brain - diagnostic imaging | Fluvoxamine - metabolism | Humans | Male | Piperazines - metabolism | Positron-Emission Tomography | Receptors, sigma - genetics | Paroxetine - metabolism | Brain - metabolism | Dose-Response Relationship, Drug | Paroxetine - administration & dosage | Radiopharmaceuticals - metabolism | Fluvoxamine - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Adult | Polymorphism, Single Nucleotide | Receptors, sigma - metabolism | PET imaging | Serotonin uptake inhibitors | Radioactive tracers
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 19, pp. e69 - e71
ONCOLOGY | RECIPIENTS | SOLID-ORGAN TRANSPLANT | Lymphatic Metastasis - diagnosis | Lung Neoplasms - drug therapy | Melanoma - diagnosis | Lymph Nodes - pathology | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Fluorodeoxyglucose F18 - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Radiopharmaceuticals - metabolism | Lung Neoplasms - secondary | Skin Neoplasms - diagnosis | Dacarbazine - analogs & derivatives | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Skin Neoplasms - pathology | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Administration, Oral | Treatment Outcome | Kidney Transplantation | Positron-Emission Tomography - methods | Melanoma - secondary | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Aged | Platinum Compounds - administration & dosage | Lung Neoplasms - diagnosis | To6 | Mela5 | Mela6 | Mela7 | Diagnosis in Oncology
Journal Article
NeuroImage, ISSN 1053-8119, 11/2016, Volume 141, pp. 10 - 17
Phosphodiesterase 10A (PDE10A) is selectively expressed in the striatal regions in the brain and may play a role in modulating dopaminergic and glutamatergic...
Reproducibility of Results | Tissue Distribution - drug effects | Phosphoric Diester Hydrolases - metabolism | Radiopharmaceuticals - pharmacokinetics | Administration, Oral | Humans | Middle Aged | Phosphoric Diester Hydrolases - drug effects | Male | Molecular Imaging - methods | Positron-Emission Tomography - methods | Brain - drug effects | Brain - metabolism | Dose-Response Relationship, Drug | Phosphodiesterase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Sensitivity and Specificity | Pyridazines - administration & dosage | Protein Binding | Adult | Pyridazines - pharmacokinetics | Metabolic Clearance Rate - drug effects | Drug Monitoring | Pyrazoles - pharmacokinetics | Pets | Nervous system diseases | Analysis | Cerebellum | Dopamine | Intravenous administration | Disease | Mental disorders | Oral administration | Schizophrenia | Putamen | Studies | Brain research | Neostriatum | Tomography | Glutamatergic transmission | Pharmaceutical industry | Positron emission tomography | Drug dosages | Dopamine receptors | Phosphodiesterase
Reproducibility of Results | Tissue Distribution - drug effects | Phosphoric Diester Hydrolases - metabolism | Radiopharmaceuticals - pharmacokinetics | Administration, Oral | Humans | Middle Aged | Phosphoric Diester Hydrolases - drug effects | Male | Molecular Imaging - methods | Positron-Emission Tomography - methods | Brain - drug effects | Brain - metabolism | Dose-Response Relationship, Drug | Phosphodiesterase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Sensitivity and Specificity | Pyridazines - administration & dosage | Protein Binding | Adult | Pyridazines - pharmacokinetics | Metabolic Clearance Rate - drug effects | Drug Monitoring | Pyrazoles - pharmacokinetics | Pets | Nervous system diseases | Analysis | Cerebellum | Dopamine | Intravenous administration | Disease | Mental disorders | Oral administration | Schizophrenia | Putamen | Studies | Brain research | Neostriatum | Tomography | Glutamatergic transmission | Pharmaceutical industry | Positron emission tomography | Drug dosages | Dopamine receptors | Phosphodiesterase
Journal Article
Blood, ISSN 0006-4971, 2008, Volume 112, Issue 10, pp. 3989 - 3994
In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV) of positron emission tomography (PET) using [F-18]-fluorodeoxyglucose...
FDG-PET | TRIALS | THERAPY | METAANALYSIS | FREE SURVIVAL | CYCLES | EARLY INTERIM | REGIMEN | RADIOTHERAPY | HEMATOLOGY | STANDARD | Fluorodeoxyglucose F18 - administration & dosage | Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Neoplasm, Residual | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Risk Factors | Etoposide - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Positron-Emission Tomography - methods | Radiography | Radiopharmaceuticals - administration & dosage | Disease-Free Survival | Adolescent | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
FDG-PET | TRIALS | THERAPY | METAANALYSIS | FREE SURVIVAL | CYCLES | EARLY INTERIM | REGIMEN | RADIOTHERAPY | HEMATOLOGY | STANDARD | Fluorodeoxyglucose F18 - administration & dosage | Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Neoplasm, Residual | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Risk Factors | Etoposide - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Positron-Emission Tomography - methods | Radiography | Radiopharmaceuticals - administration & dosage | Disease-Free Survival | Adolescent | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2014, Volume 32, Issue 17, pp. 1769 - 1775
Purpose To assess the role of [F-18] fluorodeoxyglucose ([F-18] FDG) positron emission tomography/computed tomography (PET/CT) after rituximab and...
NON-HODGKINS-LYMPHOMA | ONCOLOGY | PET | CHEMOTHERAPY
NON-HODGKINS-LYMPHOMA | ONCOLOGY | PET | CHEMOTHERAPY
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2015, Volume 112, Issue 40, pp. 12468 - 12473
Neuroinflammation is associated with a broad spectrum of neurodegenerative and psychiatric diseases. The core process in neuroinflammation is activation of...
PBR28 | Neuroinflammation | Cytokines | Endotoxin | Microglia | MULTIDISCIPLINARY SCIENCES | SYSTEMIC INFLAMMATION | POSITRON-EMISSION-TOMOGRAPHY | PROTEIN 18 KDA | TRANSLOCATOR PROTEIN | MULTIPLE-SCLEROSIS | neuroinflammation | PERIPHERAL BENZODIAZEPINE-RECEPTOR | IN-VIVO | cytokines | microglia | VIVO RADIOLIGAND BINDING | endotoxin | COGNITIVE DEFICITS | Microglia - metabolism | Humans | Lipopolysaccharides - administration & dosage | Pyridines - pharmacokinetics | Male | Lipopolysaccharides - immunology | Brain - metabolism | Young Adult | Radiopharmaceuticals - metabolism | Microglia - immunology | Inflammation Mediators - metabolism | Adult | Cytokines - blood | Biomarkers - metabolism | Reproducibility of Results | Radiopharmaceuticals - pharmacokinetics | Acetamides - pharmacokinetics | Cytokines - metabolism | Carbon Radioisotopes - pharmacokinetics | Inflammation Mediators - blood | Positron-Emission Tomography - methods | Acetamides - metabolism | Pyridines - metabolism | Receptors, GABA - metabolism | Protein Binding | Carbon Radioisotopes - metabolism | Brain - immunology | Physiological aspects | Inflammation | Health aspects | Lipopolysaccharides | Biological Sciences
PBR28 | Neuroinflammation | Cytokines | Endotoxin | Microglia | MULTIDISCIPLINARY SCIENCES | SYSTEMIC INFLAMMATION | POSITRON-EMISSION-TOMOGRAPHY | PROTEIN 18 KDA | TRANSLOCATOR PROTEIN | MULTIPLE-SCLEROSIS | neuroinflammation | PERIPHERAL BENZODIAZEPINE-RECEPTOR | IN-VIVO | cytokines | microglia | VIVO RADIOLIGAND BINDING | endotoxin | COGNITIVE DEFICITS | Microglia - metabolism | Humans | Lipopolysaccharides - administration & dosage | Pyridines - pharmacokinetics | Male | Lipopolysaccharides - immunology | Brain - metabolism | Young Adult | Radiopharmaceuticals - metabolism | Microglia - immunology | Inflammation Mediators - metabolism | Adult | Cytokines - blood | Biomarkers - metabolism | Reproducibility of Results | Radiopharmaceuticals - pharmacokinetics | Acetamides - pharmacokinetics | Cytokines - metabolism | Carbon Radioisotopes - pharmacokinetics | Inflammation Mediators - blood | Positron-Emission Tomography - methods | Acetamides - metabolism | Pyridines - metabolism | Receptors, GABA - metabolism | Protein Binding | Carbon Radioisotopes - metabolism | Brain - immunology | Physiological aspects | Inflammation | Health aspects | Lipopolysaccharides | Biological Sciences
Journal Article
Blood, ISSN 0006-4971, 11/2001, Volume 98, Issue 10, pp. 2930 - 2934
Residual mediastinal masses are frequently observed in patients with Hodgkin disease (HD) after completed therapy, and the discrimination between active tumor...
Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Hodgkin Disease - pathology | Humans | Salvage Therapy | Transplantation, Autologous | Life Tables | Vinblastine - administration & dosage | False Positive Reactions | Mediastinal Neoplasms - therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Radiopharmaceuticals | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Diagnosis, Differential | Prednisone - administration & dosage | Dexamethasone - administration & dosage | False Negative Reactions | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Neoplasm Recurrence, Local - diagnosis | Bleomycin - administration & dosage | Mediastinal Neoplasms - diagnostic imaging | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Hodgkin Disease - therapy | Fibrosis | Fluorodeoxyglucose F18 | Tomography, Emission-Computed | Carmustine - administration & dosage
Hodgkin Disease - diagnostic imaging | Procarbazine - administration & dosage | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Hodgkin Disease - pathology | Humans | Salvage Therapy | Transplantation, Autologous | Life Tables | Vinblastine - administration & dosage | False Positive Reactions | Mediastinal Neoplasms - therapy | Hodgkin Disease - mortality | Vincristine - administration & dosage | Radiopharmaceuticals | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Diagnosis, Differential | Prednisone - administration & dosage | Dexamethasone - administration & dosage | False Negative Reactions | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Neoplasm Recurrence, Local - diagnosis | Bleomycin - administration & dosage | Mediastinal Neoplasms - diagnostic imaging | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Hodgkin Disease - therapy | Fibrosis | Fluorodeoxyglucose F18 | Tomography, Emission-Computed | Carmustine - administration & dosage
Journal Article
Advanced Drug Delivery Reviews, ISSN 0169-409X, 2008, Volume 60, Issue 12, pp. 1347 - 1370
Receptor-based radiopharmaceuticals are of great current interest in molecular imaging and radiotherapy of cancers, and provide a unique tool for...
Radionuclides | Diagnosis | Radiopharmaceuticals | Target-specific delivery | Radiotherapy | Organotechnetium Compounds - chemistry | Radiopharmaceuticals - chemistry | Gallium Radioisotopes - administration & dosage | Humans | Indium Radioisotopes - chemistry | Gallium Radioisotopes - chemistry | Organotechnetium Compounds - administration & dosage | Yttrium Radioisotopes - administration & dosage | Drug Delivery Systems | Radiopharmaceuticals - administration & dosage | Animals | Indium Radioisotopes - administration & dosage | Isotope Labeling | Radioisotopes - administration & dosage | Copper Radioisotopes - administration & dosage | Copper Radioisotopes - chemistry | Radioisotopes - chemistry | Yttrium Radioisotopes - chemistry | Biochemistry | radiotherapy | radiopharmaceuticals | diagnosis | target-specific delivery | radionuclides
Radionuclides | Diagnosis | Radiopharmaceuticals | Target-specific delivery | Radiotherapy | Organotechnetium Compounds - chemistry | Radiopharmaceuticals - chemistry | Gallium Radioisotopes - administration & dosage | Humans | Indium Radioisotopes - chemistry | Gallium Radioisotopes - chemistry | Organotechnetium Compounds - administration & dosage | Yttrium Radioisotopes - administration & dosage | Drug Delivery Systems | Radiopharmaceuticals - administration & dosage | Animals | Indium Radioisotopes - administration & dosage | Isotope Labeling | Radioisotopes - administration & dosage | Copper Radioisotopes - administration & dosage | Copper Radioisotopes - chemistry | Radioisotopes - chemistry | Yttrium Radioisotopes - chemistry | Biochemistry | radiotherapy | radiopharmaceuticals | diagnosis | target-specific delivery | radionuclides
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2014, Volume 20, Issue 1, pp. 9 - 14
On May 15, 2013, the U. S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals...
TRIAL | PREDNISONE | MITOXANTRONE | ONCOLOGY | INCREASED SURVIVAL | DOCETAXEL | METASTATIC PROSTATE-CANCER | CHEMOTHERAPY | ABIRATERONE | Bone Neoplasms - mortality | Radioisotopes - therapeutic use | Double-Blind Method | Prostatic Neoplasms, Castration-Resistant - radiotherapy | United States | Humans | Radioisotopes - adverse effects | Kaplan-Meier Estimate | Bone Neoplasms - secondary | Male | Treatment Outcome | Drug Approval | Radium - adverse effects | Radium - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Bone Neoplasms - radiotherapy | Animals | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Radiopharmaceuticals - adverse effects | Radiopharmaceuticals - therapeutic use | United States Food and Drug Administration
TRIAL | PREDNISONE | MITOXANTRONE | ONCOLOGY | INCREASED SURVIVAL | DOCETAXEL | METASTATIC PROSTATE-CANCER | CHEMOTHERAPY | ABIRATERONE | Bone Neoplasms - mortality | Radioisotopes - therapeutic use | Double-Blind Method | Prostatic Neoplasms, Castration-Resistant - radiotherapy | United States | Humans | Radioisotopes - adverse effects | Kaplan-Meier Estimate | Bone Neoplasms - secondary | Male | Treatment Outcome | Drug Approval | Radium - adverse effects | Radium - therapeutic use | Prostatic Neoplasms, Castration-Resistant - pathology | Bone Neoplasms - radiotherapy | Animals | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Radiopharmaceuticals - adverse effects | Radiopharmaceuticals - therapeutic use | United States Food and Drug Administration
Journal Article